%20consisting%20of%20NR,%20L-carnitine%20tartrate,%20serine,%20and%20N-acetyl-L-cysteine%20(NAC),%20could%20be%20used%20to%20treat%20Parki...){kind=link}
Nicotinamide Riboside Supplementation with Metabolic Activators Improves Cognitive Function in Parkinson’s Disease: Clinical Findings
Objectives
To investigate whether supplementation of combined metabolic activators (CMA) consisting of NR, L-carnitine tartrate, serine, and N-acetyl-L-cysteine (NAC), could be used to treat Parkinson's disease (PD) patients.
Journal
Brain Communications
Key Outcomes
- CMA supplementation did not improve motor function in PD patients.
- CMA significantly improved cognitive function, particularly in patients with low baseline MoCA scores, indicative of worsened cognitive function. However, the variability in baseline MoCA scores likely influenced the observed outcomes.
Duration
12 weeks
Dose
2000 mg*
*One dose of 1 g NR, 12.35 g L-serine, 2.55 g N-acetyl-L-cysteine, and 3.73 g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.
Study Design
Randomized, double-blind, placebo-controlled, phase II study in 48 Parkinson's disease (PD) patients